Please assess the completion status of the following clinical trial:

Trial Title: Functional Respiratory Imaging Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Subject's signed Informed Consent Form;~2. Male or female ≥ 40 years of age;~3. Current smokers or ex-smokers of at least 10 pack-years,~4. Established diagnosis of COPD~5. Post-BD Forced Expiratory Volume in one second/Forced Vital Capacity (FEV1/FVC) \< 0.7 and FEV1 ≤ 60% of predicted at V1~6. On a stable dose any non-extra fine ICS/LABA DPI twice daily regimen for at least 8 weeks before screening;~7. Presence of lung hyperinflation~8. Symptomatic subjects with COPD assessment test (CAT) score ≥ 10;~9. Documented history of ≥ 1 moderate or severe COPD exacerbation in the previous 12 months~Exclusion Criteria:~1. Pregnant or lactating woman;~2. Exacerbations defined as a sustained and acute deterioration of subject's symptoms and signs 30 days before screening;~3. A current asthma diagnosis;~4. Respiratory disorders other than COPD:~5. Cardiovascular diseases;~6. Evidence or history of other concurrent disease such as but not limited to hyperthyroidism, diabetes mellitus or other endocrine disease;~7. Medical history or current diagnosis of narrow-angle glaucoma;~8. History of lung transplant or lung reduction surgery;~9. ECG criteria: any clinically significant abnormal 12-lead ECG that in the investigator's opinion would affect efficacy or safety evaluation or place the subjects at risk;~10. Laboratory abnormalities;~11. Alcohol/drug abuse;~12. Contra-indications to Investigational medical products (IMPs), based on investigator judgement;~13. Documented Covid-19 diagnosis or its complications which have not resolved within 14 days prior to screening;~15. Positive molecular Covid-19 test within the last 72 hours before the remaining of screening activities.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CHF5993 (Type: EXPERIMENTAL): Beclometasone Dipropionate (BDP) 100 μg/inhalation + Formoterol Fumarate (FF) 6 μg/inhalation + Glycopyrronium Bromide (GB) 12.5 µg/inhalation

Based on this trial design, predict the completion outcome and termination type (if applicable).